On Tuesday, Axsome Therapeutics Inc (NASDAQ: AXSM) opened lower -3.72% from the last session, before settling in for the closing price of $116.49. Price fluctuations for AXSM have ranged from $64.11 to $139.13 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 96.67%. Company’s average yearly earnings per share was noted 45.37% at the time writing. With a float of $40.45 million, this company’s outstanding shares have now reached $49.22 million.
Considering the fact that the conglomerate employs 683 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 91.49%, operating margin of -62.54%, and the pretax margin is -64.37%.
Axsome Therapeutics Inc (AXSM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Axsome Therapeutics Inc is 17.82%, while institutional ownership is 79.14%. The most recent insider transaction that took place on Feb 13 ’25, was worth 1,558,320. In this transaction Chief Financial Officer of this company sold 12,000 shares at a rate of $129.86, taking the stock ownership to the 42,187 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Financial Officer sold 3,000 for $131.07, making the entire transaction worth $393,210. This insider now owns 42,187 shares in total.
Axsome Therapeutics Inc (AXSM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.37% per share during the next fiscal year.
Axsome Therapeutics Inc (NASDAQ: AXSM) Trading Performance Indicators
Check out the current performance indicators for Axsome Therapeutics Inc (AXSM). In the past quarter, the stock posted a quick ratio of 1.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.77, a number that is poised to hit -1.05 in the next quarter and is forecasted to reach 2.08 in one year’s time.
Technical Analysis of Axsome Therapeutics Inc (AXSM)
Compared to the last year’s volume of 0.9 million, its volume of 0.71 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 72.27%. Additionally, its Average True Range was 4.66.
During the past 100 days, Axsome Therapeutics Inc’s (AXSM) raw stochastic average was set at 57.57%, which indicates a significant increase from 57.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.82% in the past 14 days, which was lower than the 57.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $114.62, while its 200-day Moving Average is $99.39. Nevertheless, the first resistance level for the watch stands at $116.14 in the near term. At $120.13, the stock is likely to face the second major resistance level. The third major resistance level sits at $122.89. If the price goes on to break the first support level at $109.39, it is likely to go to the next support level at $106.63. Now, if the price goes above the second support level, the third support stands at $102.64.
Axsome Therapeutics Inc (NASDAQ: AXSM) Key Stats
There are currently 49,219K shares outstanding in the company with a market cap of 5.74 billion. Presently, the company’s annual sales total 385,690 K according to its annual income of -287,220 K. Last quarter, the company’s sales amounted to 118,770 K and its income totaled -74,910 K.
